Request for Applications Issued

NETRF invites innovative research applications in neuroendocrine tumors (NETs) that can bring the field closer to more effective therapies. Letters of Intent are due June 15, 2018. (MORE)

Research

10th Anniversary Research Symposium

This year marked the 10th anniversary of the NETRF Research Symposium. What started as a small and informal gathering of scientific advisors and a handful of NETRF grantees has grown to be the go-to-meeting for scientists and clinicians studying neuroendocrine cancers. (MORE)

MD Anderson Cancer Center Scientist Awarded Research Grant

Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells? If so, what happens if the enzyme is removed? Can manipulation of this enzyme slow or stop cancer cell production?

This is the direction to be taken by a newly funded researcher who hopes to identify new therapeutic targets for NETs. (MORE)

Education & Advocacy

Trusting Your Doctor

Maybe you’ve been told you had food poisoning, menopause, or colitis—when you really had cancer? Maybe your treatment in an emergency room caused a carcinoid crisis? Maybe you saw eight doctors over a period of six years before you were diagnosed with a NET?

None of these is uncommon if you are a neuroendocrine cancer patient.

A new article published by a Stanford Health Care Team including Dr. Pamela Kunz (left) explores the issue of trust in the NET patient/doctor relationship. (MORE)

PRRT Patient Profiles

A new promotional publication features the experience of five patients treated with Lutathera®, a newly approved drug delivered using Peptide Receptor Radionuclide Therapy (PRRT). The booklet was produced by the drug manufacturer AAA. Read what these patients faced during their journey and the lessons learned along the way. (MORE)

Rathan Subramaniam, MD, PhD, UT Southwestern, 2018 Houston Conference

PRRT EXPLAINED

In this 30-minute presentation, Rathan Subramaniam, MD, PhD, UT Southwestern Medical Center, explains which nuclear medicine test is best for each neuroendocrine tumor grade and gives an overview of Peptide Receptor Nucleotide Therapy (PRRT).

Watch Video

Giving & Caring

Power of Participation

by Susan Payson, NETRF Chief Development Officer

One of my goals will be to make sure that there are simple and easy ways to make a gift to NETRF no matter if it is a gift of appreciated securities, online gift, gift from a donor-advised fund or social media campaign. We receive a wide variety of donations each year. As the cost of science increases and the number of requests for competitive research grants expand so will the need for securing more gifts to NETRF, thus broadening our circle of supporters. (MORE).

Tee off for NETRF

Metro D.C. Charity Event

Register by June 1st for the Sonya Jain Charity Golf Tournament to benefit NETRF. Taking place at the legendary Reston National Golf Course from 1-7 pm, on Saturday, June 9, 2018, sponsored by eGlobalTech. Teams and individual players welcome. (MORE)

Survivors Day

National Cancer Survivors Day is Sunday, June 3

Show you are a NET survivor and celebrate life, acknowledge those living with this rare disease, and raise awareness. (MORE)

Post “I am a NET Survivor” photo to your social media.

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

321 Columbus Avenue, Suite 5R
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.